<h2 data-start="97" data-end="369">Global Oncolytic Virus Therapies Market Growing at a CAGR of 26.3% | Straits Research</h2>
<p data-start="97" data-end="369">The global <a href="https://straitsresearch.com/report/oncolytic-virus-therapies-market">oncolytic virus therapies market</a> size was valued at <strong data-start="214" data-end="233">USD 214 million</strong> in 2022 and is projected to reach <strong data-start="268" data-end="287">USD 970 million</strong> by 2031, expanding at a <strong data-start="312" data-end="329">CAGR of 26.3%</strong> during the forecast period (2023&ndash;2031).</p>
<p data-start="371" data-end="927">The oncolytic virus therapies market is witnessing rapid growth, driven by the increasing prevalence of cancer and the rising demand for innovative and targeted cancer treatments. Oncolytic virus therapies utilize genetically modified viruses to selectively infect and destroy cancer cells, making them a promising alternative to traditional treatments such as chemotherapy and radiation therapy. The market is expected to experience significant growth as these therapies gain regulatory approval and become a more common part of cancer treatment regimens.</p>
<img src="https://healthcareblog61.wordpress.com/wp-content/uploads/2025/03/3.jpg">
<h3 data-start="929" data-end="954"><strong data-start="933" data-end="954">Market Definition</strong></h3>
<p data-start="956" data-end="1617">Oncolytic virus therapy is a novel form of cancer treatment that uses viruses, specifically engineered to selectively infect and kill cancer cells, while sparing healthy cells. These viruses are often modified to increase their effectiveness in targeting cancer cells and stimulating the body's immune system to fight cancer. Oncolytic virus therapies are being explored for various types of cancers, including melanoma, glioma, and pancreatic cancer. The promising results of clinical trials and the increasing number of partnerships and investments in oncolytic virus research are expected to further accelerate the market's growth during the forecast period.</p>
<h3 data-start="1619" data-end="1677"><strong data-start="1623" data-end="1677">Highlights of the Oncolytic Virus Therapies Market</strong></h3>
<ol data-start="1679" data-end="2493">
<li data-start="1679" data-end="1832"><strong data-start="1682" data-end="1698">Market Size:</strong> The oncolytic virus therapies market was valued at <strong data-start="1750" data-end="1769">USD 214 million</strong> in 2022 and is projected to reach <strong data-start="1804" data-end="1823">USD 970 million</strong> by 2031.</li>
<li data-start="1833" data-end="1946"><strong data-start="1836" data-end="1852">Growth Rate:</strong> The market is expected to grow at a <strong data-start="1889" data-end="1906">CAGR of 26.3%</strong> during the forecast period (2023&ndash;2031).</li>
<li data-start="1947" data-end="2122"><strong data-start="1950" data-end="1982">Increased Cancer Prevalence:</strong> The rise in the global cancer burden and the growing demand for effective and targeted cancer therapies are major drivers of market growth.</li>
<li data-start="2123" data-end="2315"><strong data-start="2126" data-end="2157">Technological Advancements:</strong> Ongoing advancements in genetic engineering and virology are making oncolytic virus therapies more effective and applicable to a wider range of cancer types.</li>
<li data-start="2316" data-end="2493"><strong data-start="2319" data-end="2344">Regulatory Approvals:</strong> Increased regulatory approvals for oncolytic virus therapies are paving the way for their commercialization and widespread use in clinical settings.</li>
</ol>
<h3 data-start="2495" data-end="2535"><strong data-start="2499" data-end="2535">Questions Answered in the Report</strong></h3>
<ol data-start="2537" data-end="3122">
<li data-start="2537" data-end="2612">What is the current size of the global oncolytic virus therapies market?</li>
<li data-start="2613" data-end="2691">What are the key drivers of growth in the oncolytic virus therapies market?</li>
<li data-start="2692" data-end="2761">How is the increasing prevalence of cancer influencing the market?</li>
<li data-start="2762" data-end="2845">What are the major advancements in the development of oncolytic virus therapies?</li>
<li data-start="2846" data-end="2952">Which regions are expected to dominate the oncolytic virus therapies market during the forecast period?</li>
<li data-start="2953" data-end="3032">How are regulatory approvals impacting the oncolytic virus therapies market?</li>
<li data-start="3033" data-end="3122">What are the major companies involved in the development of oncolytic virus therapies?</li>
</ol>
<p data-start="3124" data-end="3348">You can get a <strong data-start="3138" data-end="3176">full PDF sample copy of the report</strong> @ <a href="https://straitsresearch.com/report/oncolytic-virus-therapies-market/request-sample" target="_new" rel="noopener" data-start="3179" data-end="3347">https://straitsresearch.com/report/oncolytic-virus-therapies-market/request-sample</a>.</p>
<h3 data-start="3350" data-end="3377"><strong data-start="3354" data-end="3377">Market Segmentation</strong></h3>
<p data-start="3379" data-end="3575">Access detailed segmentation @ <a href="https://straitsresearch.com/report/oncolytic-virus-therapies-market/segmentation" target="_new" rel="noopener" data-start="3410" data-end="3574">https://straitsresearch.com/report/oncolytic-virus-therapies-market/segmentation</a>.</p>
<p data-start="3577" data-end="3659">The oncolytic virus therapies market is segmented based on the following criteria:</p>
<ul data-start="3661" data-end="3955">
<li data-start="3661" data-end="3764"><strong data-start="3663" data-end="3681">By Virus Type:</strong>
<ul data-start="3684" data-end="3764">
<li data-start="3684" data-end="3706">Herpes Simplex Virus</li>
<li data-start="3709" data-end="3721">Adenovirus</li>
<li data-start="3724" data-end="3734">Reovirus</li>
<li data-start="3737" data-end="3753">Vaccinia Virus</li>
<li data-start="3756" data-end="3764">Others</li>
</ul>
</li>
<li data-start="3765" data-end="3862"><strong data-start="3767" data-end="3786">By Application:</strong>
<ul data-start="3789" data-end="3862">
<li data-start="3789" data-end="3799">Melanoma</li>
<li data-start="3802" data-end="3810">Glioma</li>
<li data-start="3813" data-end="3832">Pancreatic Cancer</li>
<li data-start="3835" data-end="3851">Ovarian Cancer</li>
<li data-start="3854" data-end="3862">Others</li>
</ul>
</li>
<li data-start="3863" data-end="3955"><strong data-start="3865" data-end="3881">By End-User:</strong>
<ul data-start="3884" data-end="3955">
<li data-start="3884" data-end="3895">Hospitals</li>
<li data-start="3898" data-end="3926">Cancer Research Institutes</li>
<li data-start="3929" data-end="3955">Pharmaceutical Companies</li>
</ul>
</li>
</ul>
<h3 data-start="3957" data-end="4016"><strong data-start="3961" data-end="4016">Key Players in the Oncolytic Virus Therapies Market</strong></h3>
<ul data-start="4018" data-end="4244">
<li data-start="4018" data-end="4030">Amgen Inc.</li>
<li data-start="4031" data-end="4056">Oncolytics Biotech Inc.</li>
<li data-start="4057" data-end="4078">Turnstone Biologics</li>
<li data-start="4079" data-end="4114">Shanghai Sunway Biotech Co., Ltd.</li>
<li data-start="4115" data-end="4129">Targovax ASA</li>
<li data-start="4130" data-end="4150">Viralytics Limited</li>
<li data-start="4151" data-end="4174">Replimune Group, Inc.</li>
<li data-start="4175" data-end="4204">Sorrento Therapeutics, Inc.</li>
<li data-start="4205" data-end="4230">Genentech, Inc. (Roche)</li>
<li data-start="4231" data-end="4244">AstraZeneca</li>
</ul>
<p data-start="4246" data-end="4562">These key players are focusing on partnerships, acquisitions, and the development of new oncolytic virus therapies to strengthen their market presence and expand their product portfolios. Increased research and clinical trials are also being undertaken to improve the efficacy and safety profiles of these therapies.</p>
<h3 data-start="4564" data-end="4604"><strong data-start="4568" data-end="4602">Dominated Region: Asia-Pacific</strong></h3>
<p data-start="4605" data-end="4987">The Asia-Pacific region is expected to dominate the oncolytic virus therapies market, driven by factors such as a large population base, increased healthcare spending, and a rise in cancer cases. The growing adoption of advanced therapies and technological innovations in countries like China, Japan, and India is expected to contribute significantly to market growth in the region.</p>
<h3 data-start="4989" data-end="5029"><strong data-start="4993" data-end="5027">Fastest Growing Region: Europe</strong></h3>
<p data-start="5030" data-end="5479">Europe is expected to be the fastest-growing region for the oncolytic virus therapies market during the forecast period. The region benefits from strong healthcare infrastructure, increased investment in cancer research, and supportive regulatory frameworks for the development and commercialization of oncolytic virus therapies. The rising incidence of cancer and the growing number of clinical trials are expected to boost market growth in Europe.</p>
<p data-start="5481" data-end="5693">For more information, queries, or customization before buying, visit @ <a href="https://straitsresearch.com/buy-now/oncolytic-virus-therapies-market" target="_new" rel="noopener" data-start="5552" data-end="5692">https://straitsresearch.com/buy-now/oncolytic-virus-therapies-market</a>.</p>
<p data-start="5700" data-end="5829"><strong data-start="5700" data-end="5715">Contact Us:</strong><br data-start="5715" data-end="5718" />Email: <a rel="noopener" data-start="5725" data-end="5750">sales@straitsresearch.com</a><br data-start="5750" data-end="5753" />Phone: +1 646 905 0080 (US), +91 8087085354 (India), +44 203 695 0070 (UK)</p>
